Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Authors : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pages : 199-209

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Authors : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Year : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 262-273.e7

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.

Authors : Eiger D, Brandão M, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.

Authors : Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart-Gebhart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E
Year : 2020
Journal : Br J Cancer
Volume : 122
Pages : 1453-1460

Targeted therapy for breast cancer in older patients.

Authors : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Year : 2020
Journal : J Geriatr Oncol
Volume : 11
Pages : 380-388

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Authors : Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K
Year : 2020
Journal : Ann Oncol
Volume : 31
Pages : 171-190

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Authors : Pondé N, Ameye L, Lambertini M, Paesmans M, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Year : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 174-181.e3

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.

Authors : Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L
Year : 2020
Journal : Int J Cancer
Volume : 147
Pages : 160-169

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Authors : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Year : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pages : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Authors : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Year : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pages : 161-171

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).

Authors : Eiger D, Wagner M, Pondé NF, Nogueira MS, Buisseret L, de Azambuja E
Year : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pages : 723-725

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.

Authors : Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.

Authors : Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart-Gebhart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, De Braud FG, Iorio MV, Verderio P, Daidone MG
Year : 2020
Journal : Int J Mol Sci
Volume : 21

Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?

Authors : Caparica R, de Angelis C, Fêde Â, Werutsky G, de Azambuja E
Year : 2020
Journal : Expert Rev Anticancer Ther
Volume : 20
Pages : 563-573

HER2-positive advanced breast cancer treatment in 2020.

Authors : Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E
Year : 2020
Journal : Cancer Treat Rev
Volume : 88
Pages : 102033

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Authors : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Year : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 2883-2891

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.

Authors : Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM
Year : 2020
Journal : Br J Cancer
Volume : 123
Pages : 694-697

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Authors : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart-Gebhart M, Gnant M, Baselga J, de Azambuja E
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1226-1238

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Authors : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Year : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 169-177